27-07-2025
LifeSci Capital Keeps Their Buy Rating on Abivax SA Sponsored ADR (ABVX)
LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Abivax SA Sponsored ADR yesterday and set a price target of $101.00. The company's shares closed last Friday at $66.49.
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Slutsky is a 4-star analyst with an average return of 11.7% and a 39.25% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Abivax SA Sponsored ADR, Cogent Biosciences, and Celldex.
Currently, the analyst consensus on Abivax SA Sponsored ADR is a Strong Buy with an average price target of $79.29, a 19.25% upside from current levels. In a report released on July 24, Morgan Stanley also upgraded the stock to a Buy with a $71.00 price target.
Based on Abivax SA Sponsored ADR's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $4.01 million and a GAAP net loss of $47.3 million. In comparison, last year the company earned a revenue of $2.33 million and had a GAAP net loss of $95.79 million
